Everads Therapy Reports Positive First-in-Human Data for Novel Suprachoroidal Drug Delivery System in Diabetic Macular Edema
Key Insights
Everads Therapy (search) published first-in-human clinical data for its suprachoroidal injector in Ophthalmology Science, demonstrating favorable safety and tolerability in diabetic macular edema (search) patients.
The open-label trial (NCT06314217) showed the device achieved rapid, posteriorly directed drug distribution using thermal imaging visualization during triamcinolone acetonide administration.
The proprietary non-sharp tissue separator technology enables controlled access to the suprachoroidal space (search) via office-based, non-surgical administration.
Everads Therapy (search) has achieved a significant milestone with the publication of positive first-in-human clinical data for its novel suprachoroidal drug delivery system in Ophthalmology Science, the peer-reviewed journal of the American Academy of Ophthalmology. The clinical study (NCT06314217) evaluated the safety and performance of the Everads Injector for suprachoroidal administration of triamcinolone acetonide suspension in patients with diabetic macular edema (search).
Clinical Trial Results Demonstrate Safety and Efficacy
The open-label trial demonstrated a favorable safety and tolerability profile, along with procedural feasibility and ease of use in an office-based setting. A key finding was the thermal imaging visualization that showed rapid, posteriorly directed drug distribution achieved with the Everads Injector.
"In this study, the Everads Injector demonstrated favorable safety, tolerability, and ease of use. Its ability to enable controlled access and achieve posteriorly directed drug distribution may differentiate Everads' approach for suprachoroidal drug delivery," said Dr. Yoreh Barak, MD, Head of Retina at Rambam Medical Center (search) and Principal Investigator of the study.
Novel Technology Platform
The Everads Injector represents a new generation of delivery technologies designed for rapid and broad drug distribution throughout the suprachoroidal space (search) via a non-surgical, office-based administration. The technology is based on a proprietary non-sharp tissue separator that accesses the space via controlled tissue separation and allows tangential delivery toward the posterior segment of the eye. This approach facilitates targeted distribution to the posterior pole and macular region.
ARVO 2026 Presentations
Building on this publication, Everads announced three presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting in Denver, Colorado. The presentations include studies on real-time infrared ocular thermography for confirming suprachoroidal delivery, standardized assessment methods using near-real surgical specimens, and infrared thermal imaging to differentiate injection patterns.
Company Background and Future Potential
Moshe Weinstein, Executive Chairman of Everads, emphasized the significance of this milestone: "This publication marks an important milestone for Everads and reinforces the potential of our platform. We see strong potential for this technology to expand the use of suprachoroidal delivery across retinal therapies, particularly for treatments that benefit from rapid, posteriorly directed distribution."
Everads Therapy (search) is advancing retinal disease treatment through its proprietary suprachoroidal delivery platform and is also developing this platform for in-office suprachoroidal buckling to treat select retinal detachments (search). The company collaborates with partners across gene therapy, cell therapy, small molecule formulations, and other modalities. Founded as a spin-out from DALI Medical Devices (search), Everads was established within RAD Biomed (search), with core technologies licensed from the laboratory of Prof. Y Rotenstreich at the Sheba Tel Hashomer Medical Center (search).